Bausch Health Companies (NYSE:BHC) Announces Earnings Results, Beats Estimates By $0.10 EPS

Bausch Health Companies (NYSE:BHC) posted its quarterly earnings results on Wednesday. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10, Briefing.com reports. The business had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. Bausch Health Companies had a negative return on equity of 850.93% and a negative net margin of 1.88%. Bausch Health Companies’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.03 earnings per share. Bausch Health Companies updated its FY 2024 guidance to EPS.

Bausch Health Companies Stock Performance

Shares of BHC stock opened at $9.78 on Friday. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The company’s 50-day moving average is $7.55 and its 200 day moving average is $7.06. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of -20.38 and a beta of 0.77.

Insider Activity at Bausch Health Companies

In related news, EVP Seana Carson sold 13,370 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the sale, the executive vice president now directly owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.12% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently commented on BHC shares. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Raymond James initiated coverage on Bausch Health Companies in a research report on Wednesday, July 10th. They issued a “market perform” rating and a $8.00 target price on the stock. Royal Bank of Canada lifted their target price on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday. Finally, Jefferies Financial Group decreased their target price on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.75.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.